Avantor
Supplies laboratory and bioproduction workflows from research through production.
Something off on this page? Send us feedback.
Profile
Provides products and services for life-science and advanced-technology customers from research through production. Its VWR distribution network and bioscience products connect laboratory research with bioproduction.
VWR Distribution & Services combines the laboratory-products and services distribution network added through the VWR acquisition with a renewed VWR commercial focus. Bioscience & Medtech Products brings together bioprocessing, liquid-handling consumables, and fluid-handling capabilities expanded through RIM Bio, Ritter, and Masterflex.
Life-science and advanced-technology customers are served from research through production through an international footprint in more than 30 countries. The modern platform combines the J.T. Baker high-purity-chemicals legacy with distribution and specialized-production capabilities.
The Revival program focuses on go-to-market, VWR relaunch, operations, and e-commerce. Segment presentation moved to VWR Distribution & Services and Bioscience & Medtech Products in 2026.
Company facts
Key statistics
Year to date +27.3% · Average volume (30d) 9.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Morgan Stanley | Reiterate | Equal Weight | $10 | $14 | |
| Jul 30, 2026 | RBC Capital | Reiterate | Sector Perform | $9 | $14 | |
| Jul 30, 2026 | Deutsche Bank | Reiterate | Hold | $25 | $13 | |
| Jul 29, 2026 | Jefferies | Upgrade | Underperform | Hold | $8 | $13 |
| Jul 6, 2026 | Evercore ISI | Target | $10 | $10.50 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $0.19 | $0.21 | +9.7% | $1.61B | $1.69B | +5.1% | +15.78% |
| Apr 29, 2026Q1 FY26 | $0.16 | $0.17 | +6.3% | $1.54B | $1.58B | +2.5% | +3.18% |
| Feb 11, 2026Q4 FY25 | $0.21 | $0.22 | +4.8% | $1.64B | $1.66B | +1.6% | −5.19% |
| Oct 29, 2025Q3 FY25 | $0.22 | $0.22 | −2.1% | $1.65B | $1.62B | −1.3% | −4.58% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.58B | $1.68B | $1.62B | $1.66B | $1.58B | $1.69B | |
| Gross profit | $534.9M | $554.1M | $526.5M | $523.9M | $500.7M | $537.0M | |
| Operating income | $147.4M | $128.8M | −$648.8M | $126.4M | $115.0M | $121.8M | |
| Net income | $64.5M | $64.7M | −$711.8M | $52.4M | $43.3M | $38.1M | |
| Diluted EPS | $0.09 | $0.09 | −$1.04 | $0.08 | $0.06 | $0.06 | |
| Gross margin | 33.8% | 32.9% | 32.4% | 31.5% | 31.7% | 31.7% | |
| Operating margin | 9.3% | 7.7% | -40.0% | 7.6% | 7.3% | 7.2% |
Fiscal years (4-quarter sums)FY21 $7.39B · FY22 $7.51B · FY23 $6.97B · FY24 $6.78B · FY25 $6.55B
Revenue by product · Q2 FY26
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $306.8M · Total debt $3.70B · Total assets $11.60B · Shareholders' equity $5.63B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 676.36M · Float 657.88M · 97.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Dodge & Cox | 120.02M | 17.75% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 70.28M | 10.39% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 31.34M | 4.63% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 30.80M | 4.55% | 13F | Aug 13, 2026 |
| Greenhaven Associates Inc | 24.64M | 3.64% | 13F | Jul 28, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 8, 2026 | Gregory T. Lucier | director | +10,000 | $8.32 |
| May 1, 2026 | Simon Dingemans | director | +25,000 | $8.14 |
| Mar 10, 2026 | Sanjeev K. Mehra | director | +125,000 | $8.01 |
| Feb 19, 2026 | Gregory T. Lucier | director | +50,000 | $9.16 |
| Feb 12, 2026 | Gregory L. Summe | director | +100,000 | $9.40 |
Peers
- Thermo Fisher Scientific
Broad laboratory distribution, reagents, consumables, and bioprocess overlap
- Danaher
Bioprocess filtration, chromatography, and single-use workflow overlap
- Agilent Technologies
Analytical laboratory instruments, consumables, software, and services overlap
- Repligen
Focused bioprocess filtration, chromatography, and fluid-management overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Avantor | $14.58 | −0.03% | $9.86B | — | 16.9 | 1.5 | +0.5% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Repligen | $181.00 | +2.72% | $9.95B | 241.5 | 78.1 | 12.7 | +11.9% |
| Median | 35.9 | 24.1 | 6.0 | +9.3% |